Global Dacryocystitis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Indication;

Acute, Chronic and Other Indications.

By Distrubution Channel;

Institutional Sales and Retail Sales.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn121688785 Published Date: March, 2025 Updated Date: April, 2025

Introduction

Global Dacryocystitis Market (USD Million), 2021 - 2031

In the year 2024, the Global Dacryocystitis Market was valued at USD 362.95 million. The size of this market is expected to increase to USD 510.71 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.0%.

The dacryocystitis market is experiencing significant growth driven by several factors, including the increasing prevalence of eye infections, technological advancements, and growing clinical research leading to new product launches. Research conducted by the IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) highlights that chronic dacryocystitis, characterized by mucoid discharge, chronic conjunctivitis, and other symptoms, is more prevalent than acute dacryocystitis.

One of the key drivers of market growth is the rising incidence of eye disorders, particularly among the elderly population. Age-related changes in eye anatomy can lead to lacrimal duct obstruction, increasing the risk of dacryocystitis. As the global population continues to age, the demand for treatments for dacryocystitis is expected to increase correspondingly.

Moreover, the growing prevalence of eye diseases is expected to fuel the demand for dacryocystitis treatments in the foreseeable future. Dacryocystitis, characterized by symptoms such as redness and pain in the eye's lower corner, affects a significant portion of the population, with a notable percentage progressing from congenital dacryocele. Consequently, there is a heightened need for effective management of dacryocystitis.

Furthermore, advancements in medical technology have facilitated the development of more efficient and less invasive surgical procedures for treating dacryocystitis, such as endoscopic dacryocystorhinostomy (DCR) and balloon dacryoplasty. These innovative techniques offer improved outcomes, faster recovery times, and reduced complications, making them increasingly favored by both patients and healthcare providers alike.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By Distrubution Channel
    3. Market Snapshot, By Region
  4. Global Dacryocystitis Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Eye Infections
        2. Growing Clinical Research and New Product Development
        3. Technological Advancements
      2. Restraints
        1. Limited Healthcare Expenditure in Developing Economies
        2. Low Patient Awareness
      3. Opportunities
        1. Growing Geriatric Population
        2. Increasing Focus on Early Diagnosis
        3. Expansion in Emerging Markets
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Dacryocystitis Market, By Indication, 2021 - 2031 (USD Million)
      1. Acute
      2. Chronic
      3. Other Indications
    2. Global Dacryocystitis Market, By Distrubution Channel, 2021 - 2031 (USD Million)
      1. Institutional Sales
      2. Retail Sales
    3. Global Dacryocystitis Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer Inc
      2. Aurobindo Pharma
      3. Orex Pharma Pvt Ltd
      4. Nosch
      5. Mylan NV
  7. Analyst Views
  8. Future Outlook of the Market